MTOR and non-small cell lung carcinoma: In our previous study, FGFC1 was treated with Erlotinib-Resistant Non-Small Cell Lung Cancer (NSCLC) cells and the study report showed that FGFC1 triggered the NSCLC cells apoptosis based on their concentration, and downregulated the phosphorylation of protein EGFR, protein kinase B (Akt), phosphatidylinositol 3-kinase (PI3K), and mTOR in H1975 cells (Yan et al., 2022).